Skip to main content

Table 5 Estimates the impact of the NHIC policy on the monthly proportion of usage

From: How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data

Variable

Lenvatinib

Sorafenib

β

t

P

95%CI

β

t

P

95%CI

β0

5.173

4.760

<0.001

2.959 ~ 7.386

8.333

8.000

<0.001

6.211 ~ 10.454

β1

0.137

1.300

0.203

-0.078 ~ 0.352

0.070

0.740

0.465

-0.123 ~ 0.264

β2

6.443

3.210

0.003

2.354 ~ 10.532

2.857

1.970

0.057

-0.096 ~ 5.810

β3

0.039

0.190

0.848

-0.371 ~ 0.448

-0.702

-4.450

<0.001

-1.024~-0.381

Back to article page

International Journal for Equity in Health

ISSN: 1475-9276

Contact us